

## **CureVac Earns Repeat Recognition by LexisNexis® as One of the World's Top Innovators**

- CureVac among global top 100 most fast-paced innovators for third consecutive year in acknowledgment of its innovative strength and extensive intellectual property portfolio
- The company holds one of the broadest intellectual property portfolios in mRNA technology

**TÜBINGEN, Germany/ BOSTON, USA – February 18, 2025** – CureVac N.V. (Nasdaq: CVAC), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (“mRNA”), today announced its recognition as a *Top 100 Global Innovator* in the [Innovation Momentum 2025](#) report by LexisNexis®. The renowned LexisNexis “Top 100 Global Innovators list” recognized the 100 most dynamic companies worldwide that are driving innovation across their businesses and industries, based on the quality and advancement of their patent portfolios. CureVac has previously received the recognition twice, in 2023 and 2024.

“CureVac’s extensive intellectual property portfolio, built on more than two decades of pioneering work in mRNA science, continues to rank among the most influential and dynamic in the field,” said Dr. Alexander Zehnder, Chief Executive Officer of CureVac. “Being recognized for the third consecutive year by LexisNexis as one of the world’s Top 100 Global Innovators underscores not only the enduring strength of our patent estate but also the ongoing value of our scientific contributions to the future of medicine. Our foundational innovations have played a vital role in shaping the mRNA field and supporting global public health, and we remain committed to advancing the boundaries of this transformative technology.”

The Innovation Momentum methodology identifies companies with patents that outperform their peers based on the potential to lead to further inventions and the scope of market protection, rewarding companies with small but high-quality portfolios or those with more extensive holdings that are well-maintained over time. Innovation Momentum builds on the Patent Asset Index, a unique patent evaluation methodology featured in the analytics platform LexisNexis® PatentSight®.

As the pioneer of mRNA therapeutics, CureVac developed proprietary foundational technologies over the last 25 years related to mRNA design, delivery and manufacturing, which materially contributed to the development of safe and efficacious COVID-19 vaccines as well as many other advances. Today, the company holds one of the broadest and most diversified patent portfolios in the field with approximately 1,000 issued patents covering mRNA technology, manufacturing and mRNA-based vaccines and therapies.

### **About CureVac**

CureVac (Nasdaq: CVAC) is a pioneering multinational biotech company founded in 2000 to advance the field of messenger RNA (mRNA) technology for application in human medicine. In more than two decades of developing, optimizing, and manufacturing this versatile biological molecule for medical purposes, CureVac has introduced and refined key underlying technologies that were essential to the production of mRNA vaccines against COVID-19, and is currently laying the groundwork for application of mRNA in new therapeutic areas of major unmet need. CureVac is leveraging mRNA technology, combined with advanced omics and computational tools, to design and develop off-the-shelf and personalized cancer vaccine product candidates. It also develops programs in prophylactic vaccines

and in treatments that enable the human body to produce its own therapeutic proteins. Headquartered in Tübingen, Germany, CureVac also operates sites in the Netherlands, Belgium, Switzerland, and the U.S. Further information can be found at [www.curevac.com](http://www.curevac.com).

#### **CureVac Media and Investor Relations Contact**

Dr. Sarah Fakh, Vice President Corporate Communications and Investor Relations

CureVac, Tübingen, Germany

T: +49 7071 9883-1298

M: +49 160 90 496949

[sarah.fakh@curevac.com](mailto:sarah.fakh@curevac.com)

#### **Forward-Looking Statements of CureVac**

This press release contains statements that constitute “forward looking statements” as that term is defined in the United States Private Securities Litigation Reform Act of 1995, including statements that express the opinions, expectations, beliefs, plans, objectives, assumptions or projections of CureVac N.V. and/or its wholly owned subsidiaries CureVac SE, CureVac Manufacturing GmbH, CureVac Inc., CureVac Swiss AG, CureVac Corporate Services GmbH, CureVac Belgium SA and CureVac Netherlands B.V. (the “company”) regarding future events or future results, in contrast with statements that reflect historical facts. Examples include discussion of the potential efficacy of the company’s vaccine and treatment candidates and the company’s strategies, financing plans, cash runway expectations, the timing and impact of restructuring, growth opportunities and market growth. In some cases, you can identify such forward-looking statements by terminology such as “anticipate,” “intend,” “believe,” “estimate,” “plan,” “seek,” “project,” “expect,” “may,” “will,” “would,” “could,” “potential,” “intend,” or “should,” the negative of these terms or similar expressions. Forward-looking statements are based on management’s current beliefs and assumptions and on information currently available to the company. However, these forward-looking statements are not a guarantee of the company’s performance, and you should not place undue reliance on such statements. Forward-looking statements are subject to many risks, uncertainties and other variable circumstances, including negative worldwide economic conditions and ongoing instability and volatility in the worldwide financial markets, ability to obtain funding, ability to conduct current and future preclinical studies and clinical trials, the timing, expense and uncertainty of regulatory approval, reliance on third parties and collaboration partners, ability to commercialize products, ability to manufacture any products, possible changes in current and proposed legislation, regulations and governmental policies, pressures from increasing competition and consolidation in the company’s industry, the effects of the COVID-19 pandemic on the company’s business and results of operations, ability to manage growth, reliance on key personnel, reliance on intellectual property protection, ability to provide for patient safety, fluctuations of operating results due to the effect of exchange rates, delays in litigation proceedings, different judicial outcomes or other factors. Such risks and uncertainties may cause the statements to be inaccurate and readers are cautioned not to place undue reliance on such statements. Many of these risks are outside of the company’s control and could cause its actual results to differ materially from those it thought would occur. The forward-looking statements included in this press release are made only as of the date hereof. The company does not undertake, and specifically declines, any

obligation to update any such statements or to publicly announce the results of any revisions to any such statements to reflect future events or developments, except as required by law.

For further information, please reference the company's reports and documents filed with the U.S. Securities and Exchange Commission (the "SEC"). You may get these documents by visiting EDGAR on the SEC website at [www.sec.gov](http://www.sec.gov).